Ritlecitinib (Litfulo) is a cutting-edge treatment designed to treat severe alopecia areata, a condition that results in significant hair loss and can have profound effects on mental and emotional well-being. The decision to introduce ritlecitinib (Litfulo) is expected to bring new hope to many who suffer from this challenging condition.

Carla, who has personally experienced the effects of alopecia, expressed her delight with the decision, stating, " The introduction of ritlecitinib (Litfulo) is a beacon of hope for many of my Upper Bann constituents and others across Northern Ireland living with severe alopecia areata. When I experienced alopecia it not only took a physical toll but impacted me emotionally and socially. As someone who has suffered from this condition in the past I want to share genuine joy to each and every person in Northern Ireland who will be able to avail of this new treatment. "

The approval of ritlecitinib (Litfulo) follows extensive trials and research, which have demonstrated its efficacy in promoting hair regrowth in individuals with severe alopecia areata. Its availability in Northern Ireland is anticipated to make a considerable positive impact on patient care and outcomes.



Carla Lockhart's advocacy for enhanced healthcare services and her support for innovative treatments like ritlecitinib (Litfulo) underscore her commitment to addressing the healthcare needs of the people of Upper Bann. The DUP MP added "This is a welcome step forward in our healthcare system, one that supports innovative treatment and will deliver real benefits to those living with all forms of alopecia across Northern Ireland,".